sorafenib has been researched along with galactose in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (galactose) | Trials (galactose) | Recent Studies (post-2010) (galactose) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 18,988 | 193 | 4,605 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y | 1 |
| Bondì, ML; Cavallaro, G; Craparo, EF; Giammona, G; Sardo, C; Serio, R; Zizzo, MG | 1 |
| Bhargava, S; Kulhari, H; Kuncha, M; Pooja, D; Sistla, R; Tunki, L; Vadithe, LN | 1 |
| Alés, E; Castillejos, MC; Cepeda-Franco, C; de la Cruz-Ojeda, P; Flores, JA; Gutiérrez-Valencia, A; Khiar, N; Mena-Barragán, T; Muntané, J; Navarro-Villarán, E; Negrete, M; Romero-Ben, E; Rosales-Barrios, C | 1 |
| Chaudhari, P; Darshan, K; Dhawan, V; Joshi, G; Lokras, A; Marwah, M; Mohanty, B; Nagarsenker, M; Saraf, M; Venkatraman, M; Warawdekar, U | 1 |
5 other study(ies) available for sorafenib and galactose
| Article | Year |
|---|---|
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles | 2008 |
Galactosylated polymeric carriers for liver targeting of sorafenib.
Topics: Animals; Antineoplastic Agents; Biological Availability; Drug Carriers; Ethylenediamines; Female; Galactose; Kidney; Liver; Lung; Mice, Inbred C57BL; Micelles; Niacinamide; Peptides; Phenylurea Compounds; Polyesters; Sorafenib; Spleen | 2014 |
Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Liberation; Galactose; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Nanoparticles; Polyethylene Glycols; Sorafenib; Tissue Distribution | 2019 |
PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors.
Topics: Antineoplastic Agents; Apoptosis; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Cell Proliferation; Endosomes; Galactose; Hep G2 Cells; Humans; Liver Neoplasms; Mannose; Mannose Receptor; Micelles; Nanoparticles; Polyacetylene Polymer; Sorafenib | 2021 |
Polysaccharide and monosaccharide guided liver delivery of Sorafenib Tosylate - A nano-strategic approach and comparative assessment of hepatospecificity.
Topics: Drug Delivery Systems; Galactose; Ligands; Liposomes; Liver; Monosaccharides; Particle Size; Polysaccharides; Sepharose; Sorafenib; Tissue Distribution | 2022 |